Replay available

ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call

ENDRA Life Sciences Inc. (NASDAQ: NDRA) Q4 2023 earnings conference call, held 2024-03-28. Replay captured from the company's public earnings webcast.

Thu, March 28, 2024 at 4:30 PMendedReplay
ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Yvonne Briggs

LHA Investor Relations

Francois Michelon

Chairman & Chief Executive Officer

Michael Thornton

Chief Technology Officer

Irina Pestrikova

Senior Director of Finance

Edward Ru

Analyst, Ascendant Capital

Replay transcript excerpt

and welcome to the Endure Life Sciences fourth quarter 2023 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the call over to Yvonne Briggs. Please go ahead. Thank you, operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to Endra Life Sciences' fourth quarter 2023 Business Update and Financial Results conference call. Earlier today, Endra issued a press release on this topic, which is available in the Investors section of Endra's website. Before we begin, please note that today's discussion will include forward-looking statements. All statements by management, other than statements of historical facts, are forward-looking statements. These include statements regarding the company's strategies, financial condition, operations, costs, plans, and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities, and expectations regarding regulatory processes, receipt of required regulatory clearances, and product launches. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward-looking statements. Please refer to the company's Form 10-K for the 2023 fiscal year and subsequent SEC filings for more information about risks and uncertainties related to forward-looking statements. In terms of the structur...

More from Endra Life Sciences Inc.